...
首页> 外文期刊>Cancer chemotherapy and pharmacology. >Safety and activity of temsirolimus and bevacizumab in patients with advanced renal cell carcinoma previously treated with tyrosine kinase inhibitors: a phase 2 consortium study
【24h】

Safety and activity of temsirolimus and bevacizumab in patients with advanced renal cell carcinoma previously treated with tyrosine kinase inhibitors: a phase 2 consortium study

机译:替西罗莫司和贝伐单抗在先前用酪氨酸激酶抑制剂治疗的晚期肾细胞癌患者中的安全性和活性:2期联合研究

获取原文
获取原文并翻译 | 示例
           

摘要

Bevacizumab or temsirolimus regimens have clinical activity in the first-line treatment of advanced renal cell carcinoma (RCC). This phase I/II trial was conducted to determine the safety of combining both agents and its efficacy in RCC patients who progressed on at least one prior anti-VEGF receptor tyrosine kinase inhibitor (RTKI) agent.
机译:贝伐单抗或西罗莫司治疗方案在晚期肾细胞癌(RCC)的一线治疗中具有临床活性。进行了这一I / II期试验,以确定两种药物联合使用的安全性及其在至少使用一种先前的抗VEGF受体酪氨酸激酶抑制剂(RTKI)药物治疗的RCC患者中的疗效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号